Neurophth Overview
- Year Founded
-
2016
- Status
-
Private
- Latest Deal Type
-
Series D
- Investors
-
18
Neurophth General Information
Description
Developer of gene therapy products designed for the treatment of genetic ophthalmic diseases. The company's technology utilizes a proprietary adeno-associated virus platform and mitochondria codon-optimized gene delivery, providing ophthalmic patients with gene therapy drugs, retinal disease treatments, glaucoma medications, vascular retinopathy therapies, and optic neuroprotection agents to address genetic eye disorders.
Contact Information
Website
www.neurophth.comCorporate Office
- 3rd Floor, Building B3, Phase II, Innovation Park
- Number 1 Jiufeng 1st Road, East Lake High-tech Development Zone
- Wuhan, Hubei 430000
- China
Corporate Office
- 3rd Floor, Building B3, Phase II, Innovation Park
- Number 1 Jiufeng 1st Road, East Lake High-tech Development Zone
- Wuhan, Hubei 430000
- China
Neurophth Timeline
Neurophth Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Later Stage VC (Series D) | 21-Aug-2026 | Completed | Generating Revenue | |||
| 8. Later Stage VC (Series C1) | 09-Aug-2023 | Completed | Generating Revenue | |||
| 7. Later Stage VC | 20-Apr-2023 | Completed | Generating Revenue | |||
| 6. Secondary Transaction - Private | 20-Apr-2023 | Completed | Generating Revenue | |||
| 5. Secondary Transaction - Private | 03-Nov-2022 | Completed | Clinical Trials - General | |||
| 4. Later Stage VC (Series C) | 04-Nov-2021 | Completed | Clinical Trials - General | |||
| 3. Early Stage VC (Series B) | 05-Feb-2021 | Completed | Clinical Trials - General | |||
| 2. Early Stage VC (Series A) | 17-Dec-2019 | $18.5M | $20.8M | Completed | Pre-Clinical Trials | |
| 1. Early Stage VC | 01-Jul-2018 | $2.32M | $2.32M | Completed | Pre-Clinical Trials |
Neurophth Comparisons
Industry
Financing
Details
Neurophth Competitors (3)
One of Neurophth’s 3 competitors is Arctic Vision, a Venture Capital-Backed company based in Shanghai, China.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Arctic Vision | Venture Capital-Backed | Shanghai, China | ||||
| ONL Therapeutics | Venture Capital-Backed | Ann Arbor, MI | ||||
| Pfizer (Vienna) | Corporation | Vienna, Austria |
Neurophth Investors (18)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Guangzhou Financial Holdings | Corporation | Minority | ||
| Hubei Provincial Science and Technology Investment Group | Venture Capital | Minority | ||
| Hubei Yangtze River Industrial Investment Group | Government | Minority | ||
| Optics Valley Financial Holdings Group | Corporation | Minority | ||
| Wuhan High Tech Medical Instrument Park | Corporation | Minority |
Neurophth FAQs
-
When was Neurophth founded?
Neurophth was founded in 2016.
-
Where is Neurophth headquartered?
Neurophth is headquartered in Wuhan, China.
-
What industry is Neurophth in?
Neurophth’s primary industry is Drug Discovery.
-
Is Neurophth a private or public company?
Neurophth is a Private company.
-
What is Neurophth’s current revenue?
The current revenue for Neurophth is .
-
How much funding has Neurophth raised over time?
Neurophth has raised $146M.
-
Who are Neurophth’s investors?
Guangzhou Financial Holdings, Hubei Provincial Science and Technology Investment Group, Hubei Yangtze River Industrial Investment Group, Optics Valley Financial Holdings Group, and Wuhan High Tech Medical Instrument Park are 5 of 18 investors who have invested in Neurophth.
-
Who are Neurophth’s competitors?
Arctic Vision, ONL Therapeutics, and Pfizer (Vienna) are competitors of Neurophth.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process